Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
| Status: | Completed |
|---|---|
| Conditions: | Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 5/5/2014 |
| Start Date: | July 2010 |
| End Date: | June 2014 |
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
The primary objective of the study is to evaluate the effectiveness and safety of
cyclobenzaprine hydrochloride extended release (Amrix 15mg/day) for the prophylaxis of
chronic migraine compared to a placebo medication. A second objective, is to find out
whether there is an improvement in quality of sleep and self-reported depression in patients
taking Amrix 15mg daily. The hypothesis is that the number of migraine days per month of
patients treated with Amrix 15mg daily will be significantly lower than those patients
treated with placebo.
cyclobenzaprine hydrochloride extended release (Amrix 15mg/day) for the prophylaxis of
chronic migraine compared to a placebo medication. A second objective, is to find out
whether there is an improvement in quality of sleep and self-reported depression in patients
taking Amrix 15mg daily. The hypothesis is that the number of migraine days per month of
patients treated with Amrix 15mg daily will be significantly lower than those patients
treated with placebo.
Inclusion Criteria:
1. males and females, aged 18 to 65, with headaches longer than 30 minutes per day for
at least 15 days per month (28 days) meeting ICHD-IIR criteria for chronic migraine.
Subjects must have headaches at least 8 days per month which are alleviated with
triptans or ergots AND/OR which have at least 1 migrainous feature (unilaterality of
headache or pain more prominent on 1 side of the head, throbbing, nausea, vomiting,
photophobia, phonophobia, increased pain with physical exertion or avoidance of
exertion)
2. subjects willing and able to perform all study-related measures including accurately
completing study diaries and instruments, maintaining stable doses of headache
preventative medications, completing study visits and obtaining blood testing as
indicated.
3. women of childbearing potential must use an acceptable method of birth control for
the duration of the study (oral contraceptives, IUD, injectable or intravaginal
contraception or barrier methods combined with spermicide)
Exclusion Criteria:
1. subjects <18 and >65 years of age
2. pregnancy or attempted pregnancy during the study
3. nursing females
4. psychiatric condition which, in the investigator's opinion will influence trial
safety or data collection
5. new daily persistent headache, hemicrania continua, chronic tension-type headache or
cluster headache diagnoses.
6. headache suspicious for and not investigated to rule out secondary headache disorder
7. angle closure glaucoma
8. urinary retention
9. hepatic impairment felt by the investigator to interfere with study safety (as
determined from history and/or prerequisite liver function testing within 1 year of
study enrollment)
10. within 14 days of MAO inhibitor use or discontinuation
11. known hypersensitivity to cyclobenzaprine hydrochloride or any component of Amrix
formulation
12. concomitant tramadol or tricyclic antidepressant use
13. history of myocardial infarction or congestive heart failure
14. hyperthyroidism
15. new start of daily preventative medication (which may influence headaches) less than
2 months preceding enrollment
16. dosage change or discontinuation of daily preventative medication (which may
influence headaches) within 1 month of trial enrollment -
We found this trial at
1
site
Click here to add this to my saved trials
